

# Guanzhang Li

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2563873/guanzhang-li-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53 papers	889 citations	13 h-index	29 g-index
56 ext. papers	1,593 ext. citations	5.5 avg, IF	4.2 L-index

#	Paper	IF	Citations
53	Canonical WNT pathway inhibition reduces ATP synthesis rates in glioblastoma stem cells.. <i>Frontiers in Bioscience</i> , <b>2022</b> , 27, 35		0
52	An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas.. <i>Brain</i> , <b>2022</b> ,	11.2	5
51	Progenitor cells derived from gene-engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology.. <i>Biotechnology Journal</i> , <b>2022</b> , e2100693	5.6	1
50	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5691	6.3	2
49	Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples. <i>Cancer Science</i> , <b>2021</b> ,	6.9	4
48	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide. <i>BMC Neurology</i> , <b>2021</b> , 21, 438	3.1	0
47	Molecular Characterization and Clinical Relevance of in Gliomas 1,018 Chinese Cohort Patients.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 777182	5.7	0
46	Comparative profiling of immune genes improves the prognoses of lower grade gliomas. <i>Cancer Biology and Medicine</i> , <b>2021</b> ,	5.2	3
45	NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 751183	5.3	1
44	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , <b>2021</b> , 19, 1-12	6.5	103
43	Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. <i>Oncologist</i> , <b>2021</b> , 26, e1460-e1469	5.7	6
42	High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma. <i>Chinese Neurosurgical Journal</i> , <b>2021</b> , 7, 22	1.6	1
41	New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 682535	4.1	0
40	Comprehensive Analysis of the Clinical and Biological Significances of Endoplasmic Reticulum Stress in Diffuse Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 619396	5.7	1
39	Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. <i>Journal of Neurosurgery</i> , <b>2021</b> , 1-9	3.2	4
38	A novel DNA repair-related nomogram predicts survival in low-grade gliomas. <i>CNS Neuroscience and Therapeutics</i> , <b>2021</b> , 27, 186-195	6.8	1
37	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , <b>2021</b> , 499, 60-73	9.9	61

36	A novel gene signature based on five immune checkpoint genes predicts the survival of glioma. <i>Chinese Neurosurgical Journal</i> , <b>2021</b> , 7, 15	1.6	
35	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. <i>CNS Neuroscience and Therapeutics</i> , <b>2021</b> , 27, 617-628	6.8	2
34	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. <i>OncoTargets and Therapy</i> , <b>2021</b> , 14, 1707-1718	4.4	3
33	Multimomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 741325	4.5	
32	Predictive value of MGMT promoter methylation on the survival of TMZ treated -mutant glioblastoma. <i>Cancer Biology and Medicine</i> , <b>2021</b> , 18, 272-282	5.2	6
31	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 800928	8.4	2
30	Functional clustering analysis identifies specific subtypes of aldehyde dehydrogenase associated with glioma immunity.. <i>Translational Cancer Research</i> , <b>2021</b> , 10, 5052-5064	0.3	0
29	Identification of an ATP metabolism-related signature associated with prognosis and immune microenvironment in gliomas. <i>Cancer Science</i> , <b>2020</b> , 111, 2325-2335	6.9	14
28	indicates assembly of M0 macrophage and more malignant phenotypes of glioma. <i>Aging</i> , <b>2020</b> , 12, 8397-8412	3.4	7
27	RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma. <i>Aging</i> , <b>2020</b> , 12, 16155-16171	5.6	11
26	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1955-1965	4.8	5
25	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. <i>Scientific Reports</i> , <b>2020</b> , 10, 16218	4.9	5
24	Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa098	0.9	0
23	A novel methylation signature predicts radiotherapy sensitivity in glioma. <i>Scientific Reports</i> , <b>2020</b> , 10, 20406	4.9	2
22	Redox Regulator Is Associated With Tumor Immunity in Glioma. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 580934	3.4	8
21	ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. <i>Scientific Reports</i> , <b>2020</b> , 10, 12682	4.9	4
20	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 581209	8.4	10
19	A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression. <i>Scientific Reports</i> , <b>2020</b> , 10, 18420	4.9	3

18	RGS16 promotes glioma progression and serves as a prognostic factor. <i>CNS Neuroscience and Therapeutics</i> , <b>2020</b> , 26, 791-803	6.8	6
17	Transcriptomic Profiling Identifies a DNA Repair-Related Signature as a Novel Prognostic Marker in Lower Grade Gliomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 2079-2086	4	5
16	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. <i>JCI Insight</i> , <b>2019</b> , 5,	9.9	13
15	A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 439-447	4.9	26
14	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. <i>Disease Markers</i> , <b>2018</b> , 2018, 5975216	3.2	8
13	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. <i>Cancer Cell International</i> , <b>2018</b> , 18, 107	6.4	21
12	CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high-grade glioma. <i>Oncology Reports</i> , <b>2018</b> , 40, 2036-2046	3.5	14
11	Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling. <i>Aging</i> , <b>2018</b> , 10, 1977-1988	5.6	5
10	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 1190	9.8	27
9	Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. <i>Cancer Science</i> , <b>2018</b> , 109, 2697-2705	6.9	44
8	Tumor Purity as an Underlying Key Factor in Glioma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6279-6291	12.9	170
7	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. <i>OncoImmunology</i> , <b>2017</b> , 6, e1328339	7.2	74
6	The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2177-2185	12.9	8
5	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. <i>Oncotarget</i> , <b>2016</b> , 7, 16384-95	3.3	40
4	ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. <i>Oncoscience</i> , <b>2016</b> , 3, 258-265	0.8	31
3	FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. <i>Oncotarget</i> , <b>2016</b> , 7, 84587-84593	3.3	8
2	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. <i>OncoImmunology</i> , <b>2016</b> , 5, e1196310	7.2	116
1	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients		8

